Beyond Equity: Extreme Innovation in Financing for Public Biotechs

In today’s turbulent market backdrop, both life science companies and investors are required to think beyond traditional equity and debt raises and consider novel financing strategies that can deliver growth capital to companies in deal structures that also balance the risk-return expectations of their investors. The current environment has spawned an emergence of creative solutions, new partnerships and innovative dealmaking to do just that. This panel discusses various approaches and considerations, and why panelists believe these new financing pathways are good for the industry - and here to stay. Join this business of biotech panel as panelists explore the latest investing trends and how companies can enter innovative financing deals that enable them to meet their near-term business goals and build long-term enterprise value.